Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Bio-Techne Corp (NASDAQ: TECH) was $48.31 for the day, down -3.09% from the previous closing price of $49.85. In other words, the price has decreased by -$3.09 from its previous closing price. On the day, 2.21 million shares were traded.
Ratios:
Our analysis of TECH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 53.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.31. For the most recent quarter (mrq), Quick Ratio is recorded 2.58 and its Current Ratio is at 3.71. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on May 30, 2025, initiated with a Overweight rating and assigned the stock a target price of $59.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 14 ’25 when Herr Amy E. sold 1,860 shares for $65.96 per share. The transaction valued at 122,691 led to the insider holds 1,976 shares of the business.
JOSHUA MOLHO bought 1,860 shares of TECH for $122,691 on Feb 14 ’25. On Jan 27 ’25, another insider, Kelderman Kim, who serves as the Chief Executive Officer of the company, sold 13,392 shares for $77.29 each. As a result, the insider received 1,035,013 and left with 39,004 shares of the company.
Valuation Measures:
As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 58.89, and their Forward P/E ratio for the next fiscal year is 23.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.27 while its Price-to-Book (P/B) ratio in mrq is 3.75.
Stock Price History:
Over the past 52 weeks, TECH has reached a high of $83.62, while it has fallen to a 52-week low of $46.01. The 50-Day Moving Average of the stock is -4.90%, while the 200-Day Moving Average is calculated to be -27.36%.
Shares Statistics:
A total of 156.76M shares are outstanding, with a floating share count of 154.99M. Insiders hold about 1.13% of the company’s shares, while institutions hold 104.60% stake in the company.
Earnings Estimates
Currently, 12.0 analysts are dedicated to thoroughly evaluating and rating the performance of Bio-Techne Corp (TECH) in the stock market.The consensus estimate for the next quarter is $0.44, with high estimates of $0.47 and low estimates of $0.42.
Analysts are recommending an EPS of between $2.07 and $1.88 for the fiscal current year, implying an average EPS of $1.91. EPS for the following year is $2.08, with 14.0 analysts recommending between $2.2 and $1.98.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $322.7M to a low estimate of $312.3M. As of the current estimate, Bio-Techne Corp’s year-ago sales were $306.1MFor the next quarter, 11 analysts are estimating revenue of $299.58M. There is a high estimate of $306.6M for the next quarter, whereas the lowest estimate is $296.17M.
A total of 15 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.24B, while the lowest revenue estimate was $1.21B, resulting in an average revenue estimate of $1.22B. In the same quarter a year ago, actual revenue was $1.16BBased on 14 analysts’ estimates, the company’s revenue will be $1.3B in the next fiscal year. The high estimate is $1.34B and the low estimate is $1.27B.
